TL;DR
The source material reviewed for this article does not identify an FDA-approved monthly GLP-1 injection for weight loss or diabetes. Familiar injectable products use daily or weekly schedules, while longer dosing intervals remain a research goal. Taking a weekly medicine every 10, 14, or 30 days does not make it an approved monthly product. We recommend following the product label and discussing any schedule change with the prescribing clinician.
Is There a Monthly GLP-1 Injection?

The supplied January 2026 National Academy of Medicine overview identifies products such as Wegovy, Ozempic, Zepbound, Trulicity, and Rybelsus, but it does not identify an approved once-monthly injection.
We separate three categories:
- Approved products: Medicines used according to an FDA-reviewed label.
- Investigational candidates: Products being evaluated in clinical trials.
- Compounded or off-label plans: Treatments that do not have an approved monthly label.
A true monthly product must be designed and tested to provide suitable drug exposure throughout its dosing interval. Skipping weekly doses, delaying them or combining several doses does not reproduce a purpose-built monthly formulation.
What “monthly” must mean
“Monthly” should describe a product studied for a defined monthly interval. It should not refer to:
- A missed weekly dose.
- A weekly medicine taken every 10 or 14 days.
- Several weekly doses combined into one injection.
- A compounded schedule presented as FDA approved.
- Marketing language unsupported by clinical evidence.
Approval status as of the publication date
Last reviewed: November 3, 2026.
Drug approvals can change. We recommend checking the current FDA label and approval database rather than relying on an article, advertisement or trial announcement alone. A clinical trial registration shows that research is planned or underway; it does not establish that a product is safe, effective or approved.
Approved GLP-1 Schedules vs. Long-Acting Products in Development
The phrase long-acting GLP-1 formulation can be misleading. A medicine may act longer than a daily product without being suitable for monthly use.
FDA-approved daily and weekly schedules
Current GLP-1 and related incretin products include oral and injectable options. Depending on the specific product, labeled schedules may be daily or weekly. Brands containing the same active ingredient can still have different indications, strengths, devices and instructions.
Ozempic and Wegovy, for example, both contain semaglutide, but their labels are not interchangeable. Tirzepatide brands also have distinct approved uses. Patients considering a change can review the current Zepbound dosage chart and refill schedule before speaking with a clinician.
The prescription label supplied with the medicine should take priority over a general comparison chart.
Monthly and other extended-interval candidates
Researchers are studying ways to make incretin medicines last longer, including formulations intended for less frequent injections. These products may use modified molecules, slow-release systems or other delivery methods.
Research status is not approval. A candidate may change schedules, encounter safety concerns or fail to show enough benefit. The same distinction applies to newer multi-receptor medicines. Our comparison of retatrutide versus tirzepatide explains why early findings should not be treated as an approved treatment plan.
How a Long-Acting GLP-1 Formulation Stays Active

GLP-1 receptor agonists mimic a natural hormone involved in appetite and blood sugar regulation. They can slow stomach emptying, increase fullness and reduce appetite. Some related medicines act on additional hormone receptors.
Researchers may extend a drug’s action by slowing its absorption, breakdown or removal from the body. The appropriate dosing schedule must still be established through product-specific research.
Half-life is not the dosing schedule
Half-life describes how quickly the measured amount of a drug falls in the body. It does not tell a patient when to take the next dose.
We keep these concepts separate:
- Half-life: How quickly the drug level declines.
- Dosing interval: When the approved label says to take another dose.
- Duration of effect: How long clinical effects may continue.
A long half-life does not justify taking a larger dose or creating a new schedule without medical guidance.
Extended action can come from different designs
Longer action may come from a slow-release depot, delayed absorption, molecular changes or binding mechanisms that reduce clearance. Each design behaves differently and requires its own dosing studies, safety review and prescribing instructions.
Can You Take a Weekly GLP-1 Every 10 or 14 Days?
We do not recommend changing a weekly schedule without the prescriber’s guidance. Extending the interval may make appetite control, blood sugar and side effects less predictable.
A clinician may sometimes recommend an off-label plan based on an individual patient’s needs. That does not make the schedule FDA approved or suitable for everyone.
Missed-dose rules depend on the product
There is no single missed-dose rule for all GLP-1 medicines. Instructions depend on the brand, route and time remaining before the next scheduled dose.
Anyone who misses a dose should check the current medication guide or contact the prescriber or dispensing pharmacist. Taking two doses close together or doubling a dose can increase risk and should not be done unless the product instructions specifically allow it.
Why self-directed dose spacing is not monthly dosing
A weekly formulation is designed around weekly administration. Taking it every 10 or 14 days does not establish that benefits will remain consistent or that risks will fall.
Long gaps may also affect tolerance when treatment resumes. Patients taking tirzepatide can use our 5 mg weekly dose guide to prepare for a review with their clinician.
Maintenance After Weight Loss
Maintenance is individual. It may involve continued treatment, a different dose, a clinician-directed schedule change or a plan to stop. Reaching a goal weight does not automatically create a standard maintenance dose.
We recommend documenting the medicine, dose, schedule, treatment goal, monitoring plan and next review date. Follow-up may cover weight trends, appetite, side effects, nutrition, activity, blood sugar, other medicines and monthly cost.
What a maintenance review should cover
A useful review asks whether treatment remains effective, tolerable, affordable and appropriate. The clinician and patient should also agree on what would trigger a dose change, restart or stop.
What may happen after stopping
Appetite, weight or blood sugar may change after treatment ends. That response is not a personal failure. A clinician can assess whether another treatment or closer monitoring is needed. Tapering may be used in some plans, but it is not a universal rule for the drug class.
Tradeoffs of Fewer Injections
Fewer injections may be more convenient, but convenience is only one part of treatment. A longer-acting dose may also be harder to adjust after it has been administered.
Less frequent can mean less flexible
Gradual dose escalation lets clinicians assess tolerance. Common concerns can include nausea, vomiting, diarrhea, constipation and abdominal discomfort, although risks differ by product.
Patients should review their medicine’s warnings and seek prompt care for severe symptoms. Our guide to Zepbound side effects and urgent warning signs can support that discussion.
The first month is for tolerance, not a race
Early results vary. We advise against taking extra medicine, injecting early, skipping escalation steps, combining GLP-1 products or using products sold only for research. A cautious start may be the safest route to a sustainable plan.
Would a Monthly GLP-1 Cost Less?
Not necessarily. Fewer injections do not guarantee a lower monthly price. Medication cost, dose, insurance coverage, care fees, supplies and follow-up may matter more than injection count.
Use monthly cost, not cost per shot
We recommend comparing the total recurring cost:
Medication + care fees + labs + supplies + shipping + required follow-up = total monthly cost
Before enrolling, ask whether the advertised amount is introductory, whether prices rise with the dose, what services are included and what happens if the prescription cannot be filled.
Access can differ by indication and product
Approval for diabetes is not the same as approval for weight management. Coverage can differ between brands even when they contain the same active ingredient. At usetemi.com, our refill reviews focus on the exact prescription, dose, timing and recurring cost rather than injection count alone.
FDA Approval, Compounding, and Online Claims
FDA approval applies to a specific finished product, indication, dose, schedule and label. It does not automatically extend to every formulation containing the same ingredient.
Compounded drugs are not FDA-approved finished products. An off-label prescription may be clinically appropriate in some circumstances, but it is still different from an approved monthly schedule.
Three claims that are not interchangeable
We distinguish among:
- An FDA-approved product with a monthly label.
- An investigational candidate being studied for monthly use.
- A compounded or off-label plan using a monthly schedule.
Oral products require the same scrutiny. Our tirzepatide pill safety guide explains how to separate approved medicines from unsupported online claims.
How to check an online offer
Ask for the active ingredient, concentration, dose, schedule, dispensing pharmacy, prescriber credentials, compounded status and full recurring cost. Avoid sellers offering prescription medicine without a valid prescription or products marked “research use only.”
Monthly GLP-1 Questions
How can I speed up weight loss on semaglutide?
Do not increase or accelerate a dose without clinical guidance. We recommend reviewing adherence, nutrition, activity, sleep, side effects and treatment goals with the prescriber.
How long does it take to lose 20 pounds on Ozempic?
There is no fixed timeline. Results vary with starting weight, dose, treatment duration, health, food intake, activity and tolerance. We prefer scheduled clinical reviews to promised deadlines.
Will there be a Zepbound pill?
Zepbound is an injectable tirzepatide product. Research into oral incretin medicines does not make any candidate an approved oral version of Zepbound. Check the current FDA record before accepting online claims.
What does “GLP-1” mean?
GLP-1 means glucagon-like peptide-1, a hormone involved in appetite and blood sugar regulation. Confirm the exact medicine and ingredient before comparing products or doses.
FAQ
Is there an FDA-approved monthly GLP-1 injection?
The supplied source material does not identify one. Because approvals can change, we recommend confirming the latest status through the FDA and a licensed clinician.
Is it safe to take a GLP-1 every 10 days?
Do not adopt a 10-day schedule without prescriber guidance. Changing the interval can affect treatment consistency and tolerance.
Can I combine weekly doses into one monthly dose?
No. Combining doses does not reproduce a controlled monthly release pattern and may cause excessive exposure.
Are compounded monthly GLP-1 products FDA approved?
Compounded drugs are not FDA-approved finished products. Ask for the ingredient, concentration, pharmacy, instructions and clinical rationale before accepting a compounded prescription.
Would one monthly injection cost less than weekly injections?
Not necessarily. Compare the full recurring cost, including medication, clinical care, labs, supplies and shipping.
Review Your GLP-1 Plan
Do not turn a weekly prescription into a monthly plan on your own. Use usetemi.com to request a review of your exact medicine, dose, refill schedule and ongoing cost.




